Molecular basis cor subdividing hereditary colon cancer?
- A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy. Deschoolmeester, Vanessa; Baay, Marc; Specenier, Pol; Lardon, Filip; Vermorken, Jan B. // Oncologist;Jul2010, Vol. 15 Issue 7, p699
Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent developments in gene sequencing and molecular diagnostics have led to high expectations for the identification of molecular markers to be used in optimized and tailored treatment regimens. However, many of...
- More Than "A Case of Fragile X". McGavin, Colleen L. // JAMA: Journal of the American Medical Association;5/7/2014, Vol. 311 Issue 17, p1735
The article discusses a case of a boy with fragile X syndrome. The symptoms of the syndrome are mentioned, including autistic tendencies, sensory integration issues and severe intellectual disability. It urges physicians to understand the typical presentations of common diseases and how the...
- Proof or Principle? On Economic Modeling to Guide Genomic Testing in Metastatic Colorectal Cancer. Carlson, Josh J.; Ramsey, Scott D. // JNCI: Journal of the National Cancer Institute;Dec2012, Vol. 104 Issue 23, p1779
The authors discuss a study which compared four strategies involving KRAS and BRAF mutation testing to choose the treatments for patients who were diagnosed with metastatic colorectal cancer, by Behl and colleagues, published within the issue. The study found that the best supportive care...
- MAKE THE MOVE TO MOLECULAR DIAGNOSTICS. // MLO: Medical Laboratory Observer;May2010, Vol. 42 Issue 5, p16
A quiz related to molecular diagnostics is presented.
- Online CME Quiz Questions. // JAMA: Journal of the American Medical Association;4/10/2013, Vol. 309 Issue 14, p1536
A quiz about approaches to molecular diagnosis is presented.
- Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Rumsby, Gill; William, Emma; Coulter-Mackie, Marion // Kidney International;Sep2004, Vol. 66 Issue 3, p959
Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Background. A definitive diagnosis of primary hyperoxaluria type 1 (PH1) and primary hyperoxaluria type 2 (PH2) requires the measurement of alanine:glyoxylate aminotransferase (AGT) and...
- Companies launch cancer testing service in Canada. // Biomedical Business & Technology;Jan2011, Vol. 34 Issue 1, p20
This article announces the launch by Epigenomics and Warnex Medical Laboratories of a molecular diagnostic blood testing service for colorectal cancer in Canada.
- InstabilitÃ© microsatellitaire dans le cancer colorectal. Bibeau, F.; Frugier, H.; Pedot, M.; Boissière-Michot, F. // Oncologie;Sep2012, Vol. 14 Issue 9, p525
Microsatellite instability is the molecular fingerprint of a deficient mismatch repair system. This alteration occurs in 15% of colorectal cancers, with two-third being linked to a sporadic disease, and one-third to an inheritance syndrome, the Lynch syndrome. This status, which can be assessed...
- Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Kastrinos, Fay; Steyerberg, Ewout W.; Balmaña, Judith; Mercado, Rowena; Gallinger, Steven; Haile, Robert; Casey, Graham; Hopper, John L.; LeMarchand, Loic; Lindor, Noralane M.; Newcomb, Polly A.; Thibodeau, Stephen N.; Syngal, Sapna // Gut;Feb2013, Vol. 62 Issue 2, p272
Background: Lynch syndrome is caused by germline mismatch repair (MMR) gene mutations. The PREMM1,2,6 model predicts the likelihood of a MMR gene mutation based on personal and family cancer history. Objective To compare strategies using PREMM1,2,6 and tumour testing (microsatellite instability...